Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at ...

Evaluate the expected performance of Regeneron (REGN) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery.

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer Society's annual report on cancer incidence and mortality. But there is a wide ...

Libtayo was approved in 2018 for advanced cutaneous squamous cell carcinoma, and since then has also been cleared for basal cell carcinoma and most recently first-line non-small cell lung cancer ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...